Table 2

Adverse events in the three treatment groups2-150

Variable Mesalamine group (n=10)
(n (%))
Sulphasalazine group (n=12) (n (%)) Balsalazide group (n=12) (n (%))
No adverse events152714
No patients with adverse events7  (70)10  (83)8  (67)
No patients with serious adverse events0 (0)1 (8)0 (0)
No patients with severe adverse events1 (10)3 (25)4 (33)
Most frequent adverse events (No events)
 Leucopenia (WBC <3.0×109/l)1 (10)1 (8)0 (0)
 Leucopenia (WBC ⩽ 3.5×109/l)5 (50)6 (50)2 (17)
 Headache1 (10)6 (50)0 (0)
 Nausea1 (10)4 (33)1 (8)
 Worsening diarrhoea1 (10)1 (8)4 (33)
 Fatigue1 (10)4 (33)1 (8)
  • 2-150 34 patients were screened, enrolled, and received at least one dose of study medication, and were included in the safety analysis. Elsewhere in the manuscript, results presented are for the intention to treat population (31 patients).